BPC-157

BPC-157 is a synthetic pentadecapeptide modeled on a gastric protective protein segment and is used in research exploring cytoprotection, angiogenic signaling, and extracellular-matrix (ECM) remodeling. The pill form format provides a solid-dose vehicle for laboratory investigations of formulation stability, excipient interactions, and simulated GI transit, without implying pharmacokinetic performance in humans.

Pathways: Literature reports evaluate interactions with endothelial and fibroblast signaling, including VEGF-linked cues, nitric-oxide–associated cytoprotection, and ECM turnover dynamics.
Cell/Matrix Interfaces: In vitro systems assess effects on migration (scratch/wound assays), integrin/focal-adhesion complexes, and collagen synthesis markers.
Formulation Notes (Pill Form): Solid-dose research focuses on peptide integrity in simulated gastric/intestinal fluids, moisture/oxidation protection through encapsulation matrices, and release profiles across pH-shift conditions.

Endothelial biology and angiogenesis assays • Fibroblast/keratinocyte migration and ECM remodeling • Oxidative-stress cytoprotection paradigms • Excipient compatibility and solid-dose stability modeling • Dissolution and pH-triggered release profiling in simulated GI systems.

Revitalized Health peptides are produced under cGMP-aligned conditions with pharmaceutical-grade inputs. Each BPC-157 lot is confirmed at ≥99% purity by HPLC with identity verified via LC-MS/MS. Solid-dose units are assembled under controlled humidity with appearance, uniformity, and content checks; microbial and endotoxin screening is performed to research-grade specifications. Batch Certificates of Analysis document analytical methods and results.

Store sealed containers in a cool, dry environment at 15–25 °C, protected from light and moisture. Keep desiccant in place until use. Avoid heat exposure and repeated container opening to minimize ambient humidity ingress. For long-term studies, retain aliquots under validated stability conditions and record lot/expiry metadata.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic application. Supplied exclusively to qualified professionals conducting controlled scientific investigations.

Identity: BPC-157 (pentadecapeptide, often acetate salt), a fragment attributed to human gastric juice protein; here formulated as an oral capsule/tablet.
Mode: Cytoprotective peptide with pro-repair signaling in models: promotes angiogenesis and endothelial migration (VEGF-linked), influences FAK/paxillin and nitric-oxide pathways, moderates inflammatory cytokines, and supports ECM organization (collagen deposition/alignment). Preclinical benefits reported in GI mucosa, tendon/ligament, nerve, and microvascular injury models. Oral activity reported in animals despite proteolysis, possibly via local GI actions and peptide stability strategies.
Formulation/QA: HPLC/LC-MS identity & purity; peptide content and counter-ion profile; microbial limits; disintegration/dissolution for capsules; accelerated/real-time stability (humidity/temperature); optional enteric protection. PD readouts (exploratory): wound/tendon scoring, ultrasound or MRI for tissue integrity, biomarker panels (VEGF, MMP/TIMP), cytokines, and patient-reported GI comfort. Monitoring: GI tolerability, hypersensitivity history; avoid implying disease treatment.